^
Association details:
| Biomarker: | IL6 elevation |
|---|---|
| Cancer: | Uveal Melanoma |
| Drug: | Kimmtrak (tebentafusp-tebn) (CD3 agonist, gp100 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1673 - Uveal melanoma study patients with low CD163:CD3 ratio in tumor biopsy and low serum IL-6 showed enhanced tumor shrinkage (TS) and overall survival (OS) on tebentafusp
Published date:
03/10/2021
Excerpt:
...phase I/II trial enrolling metastatic uveal melanoma patients we explored biomarkers of clinical outcomes….treated with weekly 68mcg tebentafusp after intra-patient dose escalation...Low serum IL-6 levels at baseline trended with TS (OR=2.1, p=0.09) and OS (HR=0.3, p<0.001).
Trial ID:
